Lupin Enters Chinese Respiratory Market with Tiotropium DPI Licensing Deal

has taken a significant step in its global expansion strategy by signing a licensing and supply agreement with Sino Universal Pharmaceuticals (SUP) for Tiotropium Dry Powder Inhaler (18 mcg/capsule), used in managing chronic obstructive pulmonary disease (COPD). As part of the deal, SUP will pursue regulatory approvals in China, while Lupin will manufacture the product and hold marketing authorisation. This move positions Lupin to tap into China’s rapidly growing respiratory market, where COPD affects over 100 million people, driven by aging demographics and pollution-related health concerns. The agreement enhances Lupin’s global respiratory footprint and reinforces its positioning in high-growth international markets through a product that targets a large unmet need. Follow me for more such posts, Thank You!